Alx Oncology Holdings (ALXO) Enterprise Value (2020 - 2026)

Alx Oncology Holdings has reported Enterprise Value for 8 years, with the latest figure at -$140.3 million in Q1 2026.

• Quarterly Enterprise Value fell 43.44% year-over-year to -$140.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$140.3 million (down 43.44% YoY) and the FY2025 annual result came in at -$44.8 million, up 64.94% from the prior year.
• Enterprise Value retreated to -$140.3 million in Q1 2026 per ALXO's latest filing, from -$44.8 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$44.8 million in Q4 2025 and troughed at -$316.6 million in Q1 2022.
• A 5-year average of -$176.9 million and a median of -$157.4 million in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 64.94% in 2025, then slumped 43.44% in 2026.
• Over 5 years, Enterprise Value stood at -$266.2 million in 2022, then jumped by 31.36% to -$182.7 million in 2023, then soared by 30.09% to -$127.8 million in 2024, then soared by 64.94% to -$44.8 million in 2025, then tumbled by 213.29% to -$140.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$140.3 million, -$44.8 million, and -$60.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.